Evoniks, Standalone

Evonik's Standalone Case Tested as BASF Walks Away and Jefferies Holds Its Ground

Published on 11/20/2026 at 03:50 | Editorial boerse-global.de
Evonik shares closed at €18.30 after BASF dropped its takeover plans. The focus now shifts to Evonik's restructuring and standalone value creation.
Evoniks, Standalone, Case, Tested, BASF, Walks, Away, Jefferies, Holds, Its Illustration mit AI erstellt.

Evonik shares closed Thursday at €18.30, a one-day move of -16%, after BASF abandoned its takeover ambitions. The stock edged higher in after-hours trading, but the retreat leaves investors with a single question: can Evonik create value on its own?

The answer no longer hinges on what a suitor might pay. It rests on what the specialty chemicals maker can deliver without one.

A €24 bid that no longer sets the floor

BASF's final non-binding cash offer stood at €24 per share, valuing Evonik at more than €11 billion — around €11.2 billion by BASF's own reckoning. That figure is a useful yardstick for what the German chemicals giant was willing to pay for a combination. It is not a floor for Evonik's standalone valuation.

The Ludwigshafen-based group had signalled a further moderate increase was on the table, according to Reuters. In the end, BASF judged a higher price unjustified given Evonik's standalone business outlook and the risks attached to it. The withdrawal followed two non-binding cash proposals that Evonik had rejected.

Jefferies analyst Priyanka Patel pointed to BASF's account that Evonik's management board had not engaged constructively with the approach despite the prospect of a sweetened bid. The brokerage kept Evonik at "Hold" with a €21 price target, while flagging downside risk for the shares. Bernstein's James Hooper, by contrast, saw scope for further talks — an additional scenario for investors, though hardly grounds to bank on a fresh offer.

Should investors sell immediately? Or is it worth buying Evonik?

The restructuring becomes the real test

What matters now is whether the planned job cuts lift earnings power. Evonik intends to shed a further 3,200 positions by the end of 2029, including 2,150 in Germany, according to WDR. The long timeline underscores the gap between an announced overhaul and its visible effect: progress in the business, not the headcount reduction itself, is what counts.

The cuts land in a period when higher energy and raw-material costs are weighing on the entire chemicals sector. The question for valuation is whether relief from the restructuring shows through in the business — or whether rising costs swallow it. If energy and feedstock prices stay elevated while the cost base only gradually lightens, operations could lag expectations even as the overhaul advances. In that case, Thursday's slide alone would be no argument for a rebound.

Rettig bets on going it alone

Interim chief executive Claus Rettig has made clear he wants to raise Evonik's value independently and play an active role in industry consolidation himself, the FAZ reported. Should the company succeed in cushioning cost pressure through the restructuring, the stock could regain ground without a new bid. An active part in consolidation would then be an extra option rather than a precondition for recovery.

The ownership structure fits that script. The RAG-Stiftung holds 43% of Evonik, per the FAZ, and opposed the takeover just as the North Rhine-Westphalia state government did. Reuters reports the foundation aims to cut its stake to 25.1% over time. For investors, that stance reinforces the case for valuing Evonik as a standalone company — though whether a higher market capitalisation follows depends on execution.

Dates on the calendar

BASF has scheduled a capital markets day for 24 November. Investors will watch for signals on capital allocation; any comment on the abandoned pursuit would only matter for Evonik's valuation if it genuinely changes the starting position. The possibility of further talks is not the same as a new offer.

For Evonik itself, the next milestone is 4 March, when fourth-quarter 2026 results are due, according to Reuters. Until then, the focus stays on how the company implements the job cuts and what effect begins to show in the business. As long as the overhaul makes headway and the relief becomes visible despite high costs, a recovery without a takeover looks plausible. Should that effect fail to materialise, Thursday's discount alone is unlikely to support the shares — only a concrete new approach would put the offer price back on investors' agenda.

Ad

Evonik Stock: New Analysis - 20 November

Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Evonik analysis...

Disclaimer...
en | DE000EVNK013 | EVONIKS | boerse | 70538404 |